Sandoz Group is a global leader in the development, manufacturing and distribution of generic pharmaceuticals and biosimilars. The company focuses on delivering high-quality, affordable versions of branded medicines across a range of therapeutic areas, including cardiovascular, oncology, central nervous system and anti-infectives. Its product portfolio spans tablets, capsules, injectables and complex biologics, enabling healthcare providers and patients to access essential medicines at lower cost.
With a broad footprint in over 100 countries, Sandoz operates manufacturing sites and research facilities across Europe, North America, Latin America and the Asia-Pacific region. The company’s active pharmaceutical ingredients (APIs) division supplies key raw materials to its internal manufacturing network as well as to third-party customers. Sandoz invests in continuous process innovation and digital technologies to optimize production efficiency, ensure consistent product quality and support fast time-to-market for new biosimilar launches.
Founded in 1886 as Sandoz Chemical Works in Basel, Switzerland, the business became part of Novartis in 1996 through the merger of Ciba and Sandoz. In 2023, Sandoz was spun out as a separate publicly traded entity, positioning it to chart an independent growth strategy. Today, Sandoz leverages more than a century of pharmaceutical expertise and a global supply network to address disparities in healthcare access, partnering with governments, non-governmental organizations and commercial customers to expand patient access to essential medicines.
AI Generated. May Contain Errors.
